Overview

A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo

Status:
Recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

The CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in patients with vitiligo on the body and face versus NB-UVB light alone.

Phase:

Phase 3

Details

Lead Sponsor:

Clinuvel, Inc.

Treatments:

Afamelanotide